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Abstract: Cancer-associated fibroblasts (CAF) form the basis of tumor microenvironment and
possess immunomodulatory functions by interacting with other cells surrounding tumor, including
T lymphocytes, macrophages, dendritic cells and natural killer cells. Ionizing radiation is a
broadly-used method in radiotherapy to target tumors. In mammalian cells, ionizing radiation
induces various types of DNA damages and DNA damage response. Being unspecific, radiotherapy
affects all the cells in tumor microenvironment, including the tumor itself, CAFs and immune cells.
CAFs are extremely radio-resistant and do not initiate apoptosis even at high doses of radiation.
However, following radiation, CAFs become senescent and produce a distinct combination of
immunoregulatory molecules. Radiosensitivity of immune cells varies depending on the cell type
due to inefficient DNA repair in, for example, monocytes and granulocytes. In this minireview, we
are summarizing recent findings on the interaction between CAF, ionizing radiation and immune
cells in the tumor microenvironment.
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1. Tumor Microenvironment and Radiotherapy
1.1. Cancer-Associated Fibroblasts, Tumor Microenvironment and Radiotherapy
Tumor microenvironment (TME) is a combination of tumor cells, immune cells and
cancer-associated fibroblasts (CAFs) that interact between each other and with extracellular elements [1].
Radiotherapy (RT) is a powerful, although unspecific, instrument that targets both cancer cells and
other elements of the TME, modulating immune response and physiology of CAFs [2]. Non-small
cell lung cancer (NSCLC) [3] accounts for about 85% of all lung cancers, being one of the deadliest
malignancy types globally [4,5]. Radiotherapy is associated with increased radio-resistance of tumors,
including NSCLC, likely due to the pro-tumorigenic activity of CAFs [6]. Pro-tumorigenic nature
of irradiated CAFs is explained either by direct stimulation of tumor cell viability or by inhibiting
immune cells, such as macrophages, dendritic cells, T cells and natural killers [7–11]. Moreover, one can
propose distinct mechanisms of tumor recovery following the therapy and role of CAFs in this scenario.
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First, the resurgence of tumor due to the malignant cells escaped from the radiotherapy. Second, if all
original tumor cells were killed due to the efficient radiotherapy, CAFs and TME could induce de novo
tumors. Third, radiotherapy itself damages cells surrounding tumor and some of these cells contribute
to de novo tumor growth. In any of these scenarios, the role of CAFs can be significant given their
immunosuppressive and tumor-supportive functions [8,10], and needs to be further examined.
Fibroblasts form a significant part of tumor stroma, and can be defined as cancer-associated
fibroblasts (CAF), tumor-associated fibroblasts (TAF), and cancer-associated mesenchymal stem cells
(MSC); moreover, fibrosis-associated fibroblasts (FAF) might differ from CAF on a molecular level,
suggesting that further research is necessary to characterize specific types and subtypes of fibroblasts in
cancer [1]. CAFs, as other fibroblasts, possess spindle-shaped morphology (Figure 1), although gained
increased proliferation rates [1]. CAFs are extensively described in literature, including [1,7–10,12–17].
In particular, CAFs can be defined as a heterogenous population of connective tissue cells that contribute
to cancer progression by secreting specific molecules, including growth factors, proteases, chemokines
and cytokines. These CAF-secreted factors influence adjacent tumor cells, usually inducing tumor
growth, as well as attract immune and inflammatory cells [1,10,18]. Due to the different origin and
location, multiple cellular markers may assist identifying CAFs, including vimentin, fibroblast-specific
protein 1 (FSP1), desmin, discoidin domain-containing receptor 2 (DDR2), αSMA, PDGF receptor-α
(PDGFRα), PDGFRβ, FAP, caveolin 1 (CAV1); and secrete vascular endothelial growth factor (VEGF),
as well as immunomodulatory molecules, including IL-10, TGFβ, TNF, IFNγ and IL-6 [1].
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 2 of 14 
 
CAFs in this scenario. First, the resurgence of tumor due to the malignant cells escaped from the 
radiotherapy. Second, if all original tumor cells were killed due to the efficient radiotherapy, CAFs 
and TME could induce de novo tumors. Third, radiotherapy itself damages cells surrounding tumor 
and some of these cells contribute to de novo tumor growth. In any of these scenarios, the role of 
CAFs can be significant given their immunosuppressive and tumor-supportive functions [8,10], and 
needs to be further examined. 
Fibroblasts form a significant part of tumor stroma, and can be defined as cancer-associated 
fibroblasts (CAF), tumor-associated fibroblasts (TAF), and cancer-associated mesenchymal stem cells 
(MSC); moreover, fibrosis-associated fibroblasts (FAF) might differ from CAF on a molecular level, 
suggesting that further research is necessary to characterize specific types and subtypes of fibroblasts 
in cancer [1]. CAFs, as other fibroblasts, possess spindle-shaped morphology (Figure 1), although 
gained increased proliferation rates [1]. CAFs are extensively described in literature, including [1,7–
10,12–17]. In particular, CAFs can be defined as a heterogenous population of connective tissue cells 
that contribute to cancer progression by secreting specific molecules, including growth factors, 
proteases, chemokines and cytokines. These CAF-secreted factors influence adjacent tumor cells, 
usually inducing tumor growth, as well as attract immune and inflammatory cells [1,10,18]. Due to 
the different origin and location, multiple cellular markers may assist identifying CAFs, including 
vimentin, fibroblast-specific protein 1 (FSP1), desmin, discoidin domain-containing receptor 2 
(DDR2), αSMA, PDGF receptor-α (PDGFRα), PDGFRβ, FAP, caveolin 1 (CAV1); and secrete vascular 
endothelial growth factor (VEGF), as well as immunomodulatory molecules, including IL-10, TGFβ, 
TNF, IFNγ and IL-6 [1]. 
 
Figure 1. CAFs as a component of tumor stroma. (A) Radiation influences CAF physiology and 
function. (B) The prognosis for NSCLC patients based on the CAF biomarkers. References to the 
Int. J. Mol. Sci. 2020, 21, 8635 3 of 15
Figure 1. CAFs as a component of tumor stroma. (A) Radiation influences CAF physiology and
function. (B) The prognosis for NSCLC patients based on the CAF biomarkers. References to the
Figure 1. Kilvaer et al. [16]; Tao et al., 2017 [19]; Donnem et al., 2008 [20]; Kilvaer et al., 2018 [15];
Kilvaer et al., 2015 [13]; Edlund et al., 2012 [21]; Saito et al., 2010 [22]; Wu et al., 2020 [23]; Mattsson et al.,
2015 [24]; Yokouchi et al., 2015 [25]; Hellevik et al., 2012 [12]; Hellevik et al., 2013 [9]; Grinde et al.,
2017 [26].
For radiotherapy in clinics, there are different radiation regimens with total doses ranging from
2 Gy to 74 Gy, which may include single radiation, fractionated, or hypofractionated schedules [27].
In addition to the immunomodulating features of irradiated CAFs, radiotherapy itself enhances
the viability of both cancer and associated cells in non-homologous end joining (NHEJ) and DNA
damage response (DDR)-dependent manner [28]. There are cons and pros in selected radiation
schedules. For example, high doses of radiation (over 10 Gy per time), although result in tumor cell
death, anti-tumor signaling and response, lead to severe tissue damage and potential recruitment
of immunosuppressive immune cells. Low doses delivered over multiple radiations over weeks
(2 Gy and less per time), are less harmful to the tumor itself and result in the recruitment of immune
cells, which can be damaged as well over the consequent radiations, reducing benefits of the therapy.
Intermediate radiation doses (between 2 Gy and 10 Gy) delivered in several cycles might combine
positive effects of high and low dose therapies, and show reduced negative effects [8,10]. Further
understanding of mechanisms underlying radiotherapy, particularly the effect on TME, will allow
delivering more efficient combinations of radiotherapy with chemo- or immunotherapy [8,10].
1.2. Radiotherapy and DNA Damage Response
Ionizing radiation used during the radiotherapy induces DNA breaks, including both single strand
(ssDNA) and double-strand DNA (DSB) breaks, which trigger DNA damage response (DDR) [29,30].
Radiation dose determines whether the cell will induce DDR, whether DNA lesions will be repaired,
or the cells will never recover from the cell cycle arrest, will enter senescence state or trigger apoptosis.
While radiation doses used in clinic vary from 0.1 Gy to 3 Gy, CAFs tolerate relatively high doses of
radiation, 30 Gy, without apoptosis, although doses higher than 10–12 Gy result in senescent CAFs [12].
What makes CAFs radioresistant when compared to many other cell types is an unsolved question.
One can speculate that CAFs have more efficient DNA repair, more resistant to induce cell cycle arrest
via checkpoint proteins, or less prone to trigger apoptosis due to, for example, compromised p53
pathway or high levels of pro-survival Bcl2 family proteins [31–33]. Surprisingly, DNA repair efficiency
in immune cells may also vary depending on the cell type. While B and T lymphocyte development
requires the generation of DSBs during the V(D)J recombination, and B cells have an additional DNA
repair-dependent class switch recombination process [34–36], monocytes and granulocytes lack certain
DNA repair mechanisms [37–40]. Furthermore, macrophages and dendritic cells re-express DNA
repair factors and are resistant to modest levels of DNA damage [38,39,41].
1.3. CAFs and NSCLC Prognosis
In a tumor microenvironment, there is a dynamic interaction between components of stroma
surrounding cancer cells, and a malignant component [1]. To identify potential CAF markers that can
be used for disease prognosis, several studies examined samples from a cohort including 536 to 553
NSCLC patients from Norway and Sweden [13,14,20,42]. In CAFs, high stromal expression of tyrosine
kinase receptor, i.e., platelet-derived growth factor receptor (PDGFR)α, correlated with longer survival
of patients (stages I–III). Differently, high expression of PDGFRβ had opposite outputs in Sweden
(increased survival) and Norway (poor survival), making it not reliable by itself, but potentially useful
when multiple other factors are considered [16].
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Furthermore, fibroblast activating protein 1 (FAP-1), a marker of fibroblast activation, and a
significant marker enabling to distinguish CAFs, is proposed as a biomarker for NSCLC prognosis [13].
High expression of FAP-1 in CAFs correlates with increased disease-specific survival of NSCLC
patients [13]. Although high expression of FAP-1 in CAF did not influence the recruitment of
tumor-infiltrating lymphocytes (TIFs), the patient’s survival was increased when FAP-1-expressing
CAFs are surrounded by high numbers of cytotoxic T cells [15] (Figure 1).
Additional proteins could be relevant prognostic markers, including CD99 [21], Forkhead Box F1
(FOXF1) [22], Cyclooxygenase-2 (COX-2) [24] (Figure 1). In particular, higher stromal expression of
CD99 in CAFs correlates with better survival prognosis in a study including materials from 430 NSCLC
patients [21]. Based on the study of 247 NSCLC patients, high expression levels of FOXF1 in CAFs is
rather a poor survival prognosis [22]. Finally, COX-2 expression in tumor and stromal cells of a large
group combining several cohorts and data from 1337 NSCLC patients was used by Mattsson et al. [24].
While COX-2 expression in tumor cells does not correlate with prognosis overall, one cohort suggested
a better prognosis for patients with high activity of COX-2 due to expression in stromal cells. It is likely,
however, that data on COX-2 need further validation [24].
2. Impact of Radiation on CAFs
Following ablative doses of radiation (18 Gy), human CAFs stay alive in tissue culture, although
demonstrate persistent DNA damage response (DDR) over days, and rapid senescence [12]. Irradiated
CAFs demonstrate reduced migration and invasive capacities in vitro, suggesting changes in the
expression of matrix or cytoskeleton proteins. Indeed, irradiated human CAFs possessed reduced
levels of matrix metalloproteinase MMP-1 expression, but increased levels of MMP-3 [12] (Figure 1).
Moreover, following the ablative radiation of 18 Gy, human CAFs overexpress integrins forming the
basis of collagen receptor (α2β1) and fibronectin receptor (α5β1) [12] (Figure 1).
Ablative doses of 18 Gy ionizing radiation result in changes of molecules secreted by CAFs.
In particular, irradiated human CAFs release reduced levels of angiogenic molecules, such as stromal
cell-derived factor-1 (SDF-1), angiopoietin and thrombospondin-2 (TSP-2) [9]. Moreover, irradiated
CAFs release higher levels of fibroblast growth factor bFGF, and macrophage migratory inhibitory
factor, MIF. There is no change in expression of hepatocyte growth factor, interleukins IL-6, IL-8, IL-1β
and tumor necrosis factor TNFα [9]. Furthermore, the factors released by irradiated CAFs inhibit
the migratory capacity of human umbilical vein endothelial cells (HUVECs), suggesting a beneficial
therapeutic effect of ablative doses radiation based on the in vitro study [9] (Figure 1).
In vivo models demonstrate that irradiation of CAF (iCAF) changes protumorigenic features,
reducing tumor engraftment and angiogenesis [26]. For example, CAFs facilitate tumor growth when
co-transplanted into athymic nude mice together with human cancer cells. However, CAFs pretreated
with either single 18 Gy or fractionated 3 × 6 Gy radiation regimens, are unable to stimulate tumor
growth [26]. Of note, implanted fibroblasts, both CAFs and iCAFs, are detected only in mice during the
first week following transplantation, and no longer detected during the weeks two to four, suggesting
that the transplanted CAFs and iCAFs gradually die in situ during the first days of experiment [26]
(Figure 1). It is possible that CAFs stimulate initial engraftment and growth of tumor cells and are less
important at the later stages of carcinogenesis. It is also likely that those human CAFs are replaced
by murine CAFs to continue maintaining tumor microenvironment in the trans-species experiments,
and further in vivo experiments in mice using only murine cells, both CAFs and tumors, can be
considered to figure out these aspects of tumorigenesis in real-time.
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3. Impact of Radiation on Immune Cells
3.1. Radiation and T Cells
The outcomes of anti-tumor therapies and immune responses are heterogeneous, potentially due
to the “holes” in T cell receptor repertoires, in addition to the variation of major histocompatibility
complexes and tumor neo-antigens [43]. Moreover, radiotherapy is toxic for T cells and likely for
hematopoietic progenitors that could be used to reconstitute T cell populations [44]. Following ionizing
radiation, T cell numbers may recover, although their repertoires cannot be restored. Unlike T helper
and T cytotoxic cells, regulatory T cells (Treg) are comparatively radioresistant [45]. Changes in T cell
receptor repertoire is also expected with age, making the immune system changes even more dynamic
and unpredictable when older patients undergo radiotherapy [43,44] (Figure 2).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 5 of 14 
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Figure 2. Impact of radiation on monocytes, dendritic cells (DC), macrophages, granulocytes, T cells
and natural killer (NK) cells in human model systems, unless specified otherwise. Indicated irradiation
doses are in range of clinically-relevant doses, depending on the regimens. References to the Figure 2.
Bauer et al., 2012 [40]; Ponath et al., 2018 [41]; Anton et al., 1998 [46]; Cao et al., 2004 [47]; Ponath et al.,
2019 [37]; Wang et al., 2020 [43]; Nishii et al., 1998 [48]; Deriano et al., 2005 [49]; Chen et al., 2020 [50];
Zarkone et al., 1989 [51]; Hietanen et al., 2015 [52].
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3.2. Radiation and B Cells
B cells and their precursor cells are hypersensitive to the irradiation-induced DNA damage [48].
However, using the C57BL/6 mouse model treated with 12–18 Gy of focal radiation to the tumor site,
it was shown that radiation turns B cells to act against tumorigenesis and alters B cell activation,
differentiation and clonality [53]. Irradiation induces B cell maturation and activation, as well as
increases differentiation of plasma cells specific for tumor antigens [53]. Furthermore, ionizing
radiation induces expression of CD20, which is a surface antigen found on the large proportion of
the B-lymphomas and used as a target in distinct therapy strategies, such as radio-immunotherapy
and antibody-based therapy [54]. Moreover, the cells present in distinct B cell lymphomas and
leukemias exhibit various levels of radiosensitivity. Notably, radioresistance has been observed
in B lymphoblastoids when compared to normal B cells, although the Burkitt’s lymphoma cells
showed hypersensitivity to irradiation [55]. Further, in the B cell chronic lymphocytic leukemia
(B-CLL), radioresistant and sensitive cell populations have been reported with distinct levels of NHEJ
activities [49].
3.3. Radiation and Monocytes
Monocytes are immune cells that differentiate into macrophages and myeloid lineage dendritic
cells (DC). Monocytes are hypersensitive to ionizing radiation and oxidative damages resulting in
single- and double-strand DNA breaks [39]. Monocytes lack or have low expression of DNA repair
proteins, such as X-ray cross complementing factor 1 (XRCC1), DNA ligase III (LIG3), poly-ADP-ribose
polymerase 1 (PARP1), and DNA-dependent protein kinase, catalytic subunit (DNA-PKcs), affecting
base excision repair (BER) and non-homologous end-joining (NHEJ). Both macrophages and dendritic
cells, however, upregulate these factors and show relatively normal DNA repair damage response and
DNA repair [39]. Monocytes with damaged DNA activate DNA damage response that includes ATM,
ATR, Chk1, Chk2 and p53. Stabilized p53 triggers apoptosis associated with the upregulation of death
receptor Fas and activated caspases 3, 7 and 8 [39]. Clinically-relevant doses of 0.5 Gy and 1 Gy ionizing
radiation are tolerated by dendritic cells and macrophages that efficiently repair DNA lesions. However,
doses of 0.5–1 Gy induce massive apoptosis of monocytes associated with inefficient DNA repair
(Figure 2) [39]. Lack of DNA-PKcs in human cells results in more severe defects in NHEJ-mediated DNA
repair than in mice [34,35,56,57], which can be explained by lower redundancy, and these data in human
cells, although clinically relevant, might not be identical if experiments are performed using mouse
models. Moreover, lack of PARP1, LIG3 and XRCC1 potentially abrogates alternative end-joining,
further reducing the efficiency of DSB repair in monocytes [39,58]. Higher doses of irradiation (20 Gy)
affect functions of dendritic cells, resulting in lower efficiency of antigen presentation [46] and lower
capacity to induce proliferation of T lymphocytes [47].
3.4. Radiation and Granulocytes
Granulocytes, mainly neutrophils, or polymorphonuclear neutrophilic granulocytes, arise from
the same precursor as monocytes and possess similar DNA repair defects to monocytes (Figure 3) [37].
Resembling monocytes, granulocytes also lack key DNA repair factors XRCC1, LIG3, PARP1 and
DNA-PKcs. Furthermore, a unique feature of granulocytes is lack of ATM, ATR and inability to
phosphorylate histone H2AX (γH2AX). DNA damage-dependent apoptosis is detected in T cells/PBL,
but not in granulocytes (Figure 2) [37].
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Figure 3. Interaction between CAFs, immune cells and radiation. (A) Interaction between irradiated
CAFs and T cells. (B) Interaction between irradiated CAFs and macrophages. M0, resting macrophages;
M1, polarized activated pro-inflammatory macrophages. CAF, co-culture with cancer-associated
fibroblasts; CM, conditioned medium from cancer-associated fibroblasts. Summarized from Gorchs et al.,
2015 [11] and Berzaghi et al., 2019 [7].
3.5. Radiation and Natural Killer Cells
Whole-body irradiation with doses higher than 1 Gy results in acute radiation syndrome, and doses
higher than 2 Gy lead to massive death of lymphocytes and hematopoietic progenitors, resulting in
hematological crisis [59]. While low doses of IR activate NK cells, higher doses impair NK functions [50].
Roles of NK cells are determined by activating and inhibiting receptors. Low doses of IR, such as
0.075 Gy to 0.15 Gy, trigger increased expression of IFN-γ and TNF-α in vitro, and doses of 0.1 Gy to
0.2 Gy result in NK activation in rat models in vivo (reviewed in [50]). IR induces ATM-dependent
DNA damage response in NK, which may facilitate immune response and reduce exhaustion [60].
Higher doses of IR may be tolerated by IL-2 pre-treated NK cells, which maintain their cytotoxic
functions [51]. Fractionated doses of 4 × 2.5 Gy, as well as 2 × 15 Gy, resulted in higher NK cytotoxicity
than single doses, such as 30 Gy or 10 Gy [52].
4. Crosstalk between Radiation, CAFs and Immune Cells
Unlike normal fibroblasts, CAFs suppress the immune response in tumor microenvironment [61].
High levels of CAFs in tumors are associated with poor treatment outcome and prognosis [18,62,63].
Whether radiotherapy affects the interaction between CAFs and tumor cells was recently studied
using several model systems, such as T cells [11] and macrophages [7]. It would be also important to
investigate the relationship between radiated CAFs and other immune system cells, including but not
limited to dendritic cells and natural killers.
4.1. Interaction between Irradiated CAFs and T Cells
Both iCAFs and intact CAFs possess immunosuppressive effects, i.e., by reducing proliferation
rates of human T cells [11]. Moreover, culture medium from irradiated or intact CAFs has the same
immunosuppressive effect, suggesting that it depends on regulatory molecules secreted by CAFs to
tumor microenvironment [11] rather than on physical interaction between the cells. Furthermore,
CAFs suppress the production of regulatory molecules by T cells, including interferon-gamma (IFN-γ)
and tumor necrosis factor alpha (TNF-α) [11]. Both CAFs and iCAFs block migration capacity of T cells
(Figure 2) [11].
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4.2. Interaction between Irradiated CAFs and Macrophages
Macrophages are a part of the tumor microenvironment that interacts with CAFs and tumor cells.
While CAFs influence both stimulated (M1) and unstimulated (M0) human macrophages in vitro,
irradiation (18 Gy) does not affect these interactions [7]. Medium containing molecules secreted by
CAFs, or conditioned medium, stimulates expression of CD40, CD80, CD163, CD206, IL-6 and IL-10
in M0 macrophages. Co-culture with CAFs stimulates M0 macrophages to produce CD80, CD163,
CD206, IL-6, IL-10, and nitric oxide (NO) (Figure 3). In contrast, M1 macrophages treated with CAF
conditioned medium produce less CD40, CD206, IL-6, IL-10, IL-12, TNF-α, and nitric oxide. Moreover,
molecules secreted by CAF abrogate migration of M1 macrophages [7,64] (Figure 3).
Co-culture of irradiated or intact CAFs induces M0 macrophages to produce higher levels of
CD80, CD163, CD206, IL-6, IL-10, and nitric oxide (Figure 3). Again, CAFs force M1 macrophages to
produce less CD40, CD80, IL-10, IL-12, TNF-α and nitric oxide. However, the expression of CD163 and
CD206 is increased in M1 macrophages co-cultured with CAFs (Figure 3). In summary, factors secreted
by CAFs inhibit the pro-inflammatory functions of M1 macrophages [7] (Figure 3).
4.3. Interaction between CAFs and Other Immune Cells in Radiation Context
Dendritic cells (DC) represent key immune anti-tumor response [2,65]. Tryptophan-2,3-dioxygenase
(TDO2), IL-6 and thymic stromal lymphopoietin secreted by CAFs abrogate differentiation and functions
of DC [66], resulting in increased expression of IL-10 and TGF-β, reduced expression of CD1a, CD80,
CD86, HLA-DR by DCs, infiltration of immunosuppressive regulatory T cells [67], and inability to
stimulate differentiation of T cells into T helper type 2, Th2 [68]. It would be of interest to follow on the
impact of radiated CAFs on the differentiation of monocytes to dendritic cells, including expression of
specific surface markers, as well as focus on the interaction between dendritic cells and T cells in the
presence of irradiated CAFs, or conditioned CAF medium.
Natural killer cells are immune system effectors capable to kill, for example, tumor cells and cells
infected by viruses [69]. NK communicates with the components of the tumor microenvironment,
including CAFs, dendritic cells and macrophages [70]. It would be of interest to investigate how
irradiated CAFs influence cytotoxicity of NKs, and both activating and repressing functions of NK cells.
5. Hypoxia and CAFs
Oxygen level is one of the factors determining cellular response to irradiation, and hypoxia
leads to about three-fold increased levels of radioresistance in the cells [71]. In TME, intratumoral
hypoxia is one of the major reasons for the dysfunctional neovasculature. CAFs, which is the
predominant cell type present in the tumor stroma, are involved in angiogenesis by secreting various
pro- and anti-angiogenic factors [72]. CAFs adapt to local hypoxia by changing metabolism and
increasing, for example, glycolysis, catabolic activity, autophagy, as well as enhancing the VEGF
signaling [1,17,72–74]. For instance, CAFs were reported to deregulate glucose metabolism following
epigenetic reprogramming and thus facilitating the progression of breast cancer [17]. In particular,
hypoxia and hypoxia-inducible factor 1 alpha (HIP1α) modulate CAFs metabolism in both mice
and humans; moreover, hypoxia results in normal fibroblasts to reprogram transcription and to
gain CAF-like features [17]. Moreover, in colorectal cancer, hypoxia was shown to change the
CAFs metabolism, which resulted in higher levels of TGF-β2 expression and thus chemotherapy
resistance of tumor [75]. Hypoxia was shown to trigger breast cancer growth supported by CAFs [76].
Overall, hypoxic conditions and subsequently adjusted metabolic pathways of CAFs can be taken into
consideration while developing new therapeutic strategies.
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6. Conclusions and Future Directions
The studies of the interaction between radiation, CAFs and immune cells are well in progress.
To get further in this road, it would be necessary to focus on various immune cells, including progenitor
cells of different lineages and even hematopoietic cells (Figure 4). It would be possible to include
different radiation schedules, such as low (less than 2 Gy), medium (2 Gy to 10 Gy) and high doses
(more than 10 Gy). Further, it would be necessary to consider both traditional in vitro and in vivo
research models, including cell lines, mice and rats, as well as more modern 3D cell cultures and
organoid systems, in combination with modern imaging techniques.
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 8 of 14 
 
monocytes to dendritic cells, including expression of specific surface markers, as well as focus on the 
interaction between dendritic cells and T cells in the presence of irradiated CAFs, or conditioned CAF 
medium. 
Natural killer cells are immune system effectors capable to kill, for example, tumor cells and 
cells infected by viruses [69]. NK communicates with the components of the tumor 
microenvironment, including CAFs, dendritic cells and macrophages [70]. It would be of interest to 
investigate how irradiated CAFs influence cytotoxicity of NKs, and both activating and repressing 
functions of NK cells. 
5. Hypoxia and CAFs 
Oxygen level is one of the factors determining cellular response to irradiation, and hypoxia leads 
to about three-fold increased levels of radioresistance in the cells [71]. In TME, intratumoral hypoxia 
is one of the major reasons for the dysfunctional neovasculature. CAFs, which is the predominant 
cell type present in the tumor stroma, are involved in angiogenesis by secreting various pro- and anti-
angiogenic factors [72]. CAFs adapt to local hypoxia by changing metabolism and increasing, for 
example, glycolysis, catabolic activity, autophagy, as well as enhancing the VEGF signaling [1,17,72–
74]. For instance, CAFs were reported to deregulate glucose metabolism following epigenetic 
reprogramming and thus facilitating the progression of breast cancer [17]. In particular, hypoxia and 
hypoxia-inducible factor 1 alpha (HIP1α) modulate CAFs metabolism in both mice and humans; 
moreover, hypoxia results in normal fibroblasts to reprogram transcription and to gain CAF-like 
features [17]. Moreover, in colorectal cancer, hypoxia was shown to change the CAFs metabolism, 
which resulted in higher levels of TGF-β2 expression and thus chemotherapy resistance of tumor 
[75]. Hypoxia was shown to trigger breast cancer growth supported by CAFs [76]. Overall, hypoxic 
conditions and subsequently adjusted metabolic pathways of CAFs can be taken into consideration 
while developing new therapeutic strategies. 
6. Conclusions and Future Directions 
The studies of the interaction between radiation, CAFs and immune cells are well in progress. 
To get further in this road, it would be necessary to focus on various immune cells, including 
progenitor cells of different lineages and even hematopoietic cells (Figure 4). It would be possible to 
include different radiation schedules, such as low (less than 2 Gy), medium (2 Gy to 10 Gy) and high 
doses (more than 10 Gy). Further, it would be necessary to consider both traditional in vitro and in 
vivo research models, including cell lines, mice and rats, as well as more modern 3D cell cultures and 
organoid systems, in combination with modern imaging techniques. 
 
Figure 4. Summary. Effects of radiation on cancer cells, CAFs and immune cells. Combination of 
immunotherapy and radiotherapy, or a combination of different radiation regimens, is a possible 
direction to improve treatment efficiency. Depletion of CAFs by combining radiotherapy and chemo- 
or immunotherapy might reduce pro-tumorigenic and immunosuppression activities. Monocytes and 
granulocytes lack NHEJ and BER DNA repair factors and hypersensitive to radiation. B cells, T cells, 
Figure 4. Summary. Effects of radiation on cancer cells, CAFs and immune cells. Combination of
immunotherapy and radiotherapy, or a combination of different radiation regimens, is a possible
direction to improve treatment efficiency. Depletion of CAFs by combining radiotherapy and chemo-
or immunotherapy might reduce pro-tumorigenic and immunosuppression activities. Monocytes and
granulocytes lack NHEJ and BER DNA repair factors and hypersensitive to radiation. B cells, T cells,
NK cells, macrophages and dendritic cells possess efficient DDR and DNA repair and show distinct
responses to radiation.
Furthermore, it is likely that radiotherapy will be combined with chemotherapy and
immunotherapy. Whether elimination or depletion of CAFs is beneficial for the overall successful
outcome of the therapy is an intriguing and open question. One challenge is unusual radioresistance of
CAFs that do not die at doses up to 30 Gy, but instead became senescent and maintain pro-tumorigenic
and immunosuppressive capacities [1,7–10,12,18]. The B cell lymphoma 2 (Bcl-2) family of proteins
includes factors that prevent apoptosis, for example, Bcl-xL, Bcl-2 and Mcl-1 [77]. A number of Bcl
inhibitors with potential clinical applications have been developed, such as ABT-737 and its derivatives,
including navitoclax (ABT-263) and venetoclax (ABT-199); WEHI-539 and its derivatives (A-1331852
and A-1155463); A1210477, S55746, S63845 and S64315. While ABT-199 has been already approved for
clinical usage, several other Bcl-2 inhibitors are currently in clinical trials as potential agents for cancer
chemotherapy, including ABT-263 and S63845 [77]. Thus, to eliminate CAFs from the radiated tumor
microenvironment, Bcl2 inhibitors, including A-1155463 and ABT-199, and existing anticancer drugs
can be used, for example, amsacrine, SN38, cisplatin, mitoxantrone, dactinomycin, dinaciclib, UCN-01,
bortezomib, and S63845 [77–82].
Intratumoral hypoxia is one of the principal reasons for radioresistance. Hypoxia leads
to remodeling of the CAFs expression profiles that in return facilitates angiogenesis at TME.
Neovasculature and tumor-associated modifications induced by CAFs ultimately contribute to tumor
progression, metastasis and diminish therapeutic efficacy of treatment regimens.
Future tumor treatment regimens might combine radio-, chemo- and immunotherapy,
and specifically target CAFs in addition to cancer cells.
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bFGF Basic fibroblast growth factor
CAF Cancer-associated fibroblasts




DDR DNA damage response
FAP-1 Fibroblast activating protein 1
Gy Gray, unit of ionizing radiation in the International System of Units
HLA Human leukocyte antigen
HUVEC Human umbilical vein endothelial cells





M1 Activated (polarized) pro-inflammatory macrophage
MIF Macrophage migration inhibitory factor
MMP Matrix metalloproteinase
NHEJ Non-homologous end joining
NK Natural killer cell
NO Nitric oxide
NSCLC Non-small cell lung cancer
PDGFR Platelet-derived growth factor receptor
SDF-1 Stromal cell-derived factor 1
TGF Transforming growth factor
TIF Tumor-infiltrating lymphocytes
TME Tumor microenvironment
TNF Tumor necrosis factor
TSP-2 Thrombospondin-2
VEGF Vascular endothelial growth factor
Y705 Tyrosine 705
References
1. Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 2016, 16, 582–598. [CrossRef]
2. Rodriguez-Ruiz, M.E.; Vitale, I.; Harrington, K.J.; Melero, I.; Galluzzi, L. Immunological impact of cell death
signaling driven by radiation on the tumor microenvironment. Nat. Immunol. 2020, 21, 120–134. [CrossRef]
3. Ji, X.; Ji, J.; Shan, F.; Zhang, Y.; Chen, Y.; Lu, X. Cancer-associated fibroblasts from NSCLC promote the
radioresistance in lung cancer cell lines. Int. J. Clin. Exp. Med. 2015, 8, 7002–7008.
4. Pilleron, S.; Soto-Perez-de-Celis, E.; Vignat, J.; Ferlay, J.; Soerjomataram, I.; Bray, F.; Sarfati, D. Estimated
global cancer incidence in the oldest adults in 2018 and projections to 2050. Int. J. Cancer 2020. [CrossRef]
[PubMed]
Int. J. Mol. Sci. 2020, 21, 8635 11 of 15
5. Papadaki, M.A.; Sotiriou, A.I.; Vasilopoulou, C.; Filika, M.; Aggouraki, D.; Tsoulfas, P.G.;
Apostolopoulou, C.A.; Rounis, K.; Mavroudis, D.; Agelaki, S. Optimization of the Enrichment of Circulating
Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated
with Anti-PD-1 Immunotherapy. Cancers 2020, 12, 1556. [CrossRef] [PubMed]
6. Wennerberg, E.; Lhuillier, C.; Vanpouille-Box, C.; Pilones, K.A.; Garcia-Martinez, E.; Rudqvist, N.P.;
Formenti, S.C.; Demaria, S. Barriers to Radiation-Induced In Situ Tumor Vaccination. Front. Immunol. 2017,
8, 229. [CrossRef] [PubMed]
7. Berzaghi, R.; Ahktar, M.A.; Islam, A.; Pedersen, B.D.; Hellevik, T.; Martinez-Zubiaurre, I. Fibroblast-Mediated
Immunoregulation of Macrophage Function Is Maintained after Irradiation. Cancers 2019, 11, 689. [CrossRef]
8. Hellevik, T.; Martinez-Zubiaurre, I. Radiotherapy and the tumor stroma: The importance of dose and
fractionation. Front. Oncol. 2014, 4, 1. [CrossRef]
9. Hellevik, T.; Pettersen, I.; Berg, V.; Bruun, J.; Bartnes, K.; Busund, L.T.; Chalmers, A.; Bremnes, R.;
Martinez-Zubiaurre, I. Changes in the Secretory Profile of NSCLC-Associated Fibroblasts after Ablative
Radiotherapy: Potential Impact on Angiogenesis and Tumor Growth. Transl. Oncol. 2013, 6, 66–74. [CrossRef]
10. Martinez-Zubiaurre, I.; Chalmers, A.J.; Hellevik, T. Radiation-Induced Transformation of Immunoregulatory
Networks in the Tumor Stroma. Front. Immunol. 2018, 9, 1679. [CrossRef]
11. Gorchs, L.; Hellevik, T.; Bruun, J.A.; Camilio, K.A.; Al-Saad, S.; Stuge, T.B.; Martinez-Zubiaurre, I.
Cancer-associated fibroblasts from lung tumors maintain their immunosuppressive abilities after high-dose
irradiation. Front. Oncol. 2015, 5, 87. [CrossRef] [PubMed]
12. Hellevik, T.; Pettersen, I.; Berg, V.; Winberg, J.O.; Moe, B.T.; Bartnes, K.; Paulssen, R.H.; Busund, L.T.;
Bremnes, R.; Chalmers, A.; et al. Cancer-associated fibroblasts from human NSCLC survive ablative doses of
radiation but their invasive capacity is reduced. Radiat. Oncol. 2012, 7, 59. [CrossRef] [PubMed]
13. Kilvaer, T.K.; Khanehkenari, M.R.; Hellevik, T.; Al-Saad, S.; Paulsen, E.E.; Bremnes, R.M.; Busund, L.T.;
Donnem, T.; Martinez, I.Z. Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and
Their Correlations with Tumor Molecular Markers. PLoS ONE 2015, 10, e0134965. [CrossRef] [PubMed]
14. Kilvaer, T.K.; Paulsen, E.E.; Khanehkenari, M.R.; Al-Saad, S.; Johansen, R.M.; Al-Shibli, K.; Bremnes, R.M.;
Busund, L.T.; Donnem, T. The presence of intraepithelial CD45RO+ cells in resected lymph nodes with
metastases from NSCLC patients is an independent predictor of disease-specific survival. Br. J. Cancer 2016,
114, 1145–1151. [CrossRef]
15. Kilvaer, T.K.; Rakaee, M.; Hellevik, T.; Ostman, A.; Strell, C.; Bremnes, R.M.; Busund, L.T.; Donnem, T.;
Martinez-Zubiaurre, I. Tissue analyses reveal a potential immune-adjuvant function of FAP-1 positive
fibroblasts in non-small cell lung cancer. PLoS ONE 2018, 13, e0192157. [CrossRef]
16. Kilvaer, T.K.; Rakaee, M.; Hellevik, T.; Vik, J.; Petris, L.; Donnem, T.; Strell, C.; Ostman, A.; Busund, L.R.;
Martinez-Zubiaurre, I. Differential prognostic impact of platelet-derived growth factor receptor expression
in NSCLC. Sci. Rep. 2019, 9, 10163. [CrossRef]
17. Becker, L.M.; O’Connell, J.T.; Vo, A.P.; Cain, M.P.; Tampe, D.; Bizarro, L.; Sugimoto, H.; McGow, A.K.;
Asara, J.M.; Lovisa, S.; et al. Epigenetic Reprogramming of Cancer-Associated Fibroblasts Deregulates
Glucose Metabolism and Facilitates Progression of Breast Cancer. Cell Rep. 2020, 31, 107701. [CrossRef]
18. Kalluri, R.; Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6, 392–401. [CrossRef]
19. Tao, L.; Huang, G.; Song, H.; Chne, Y.; Chen, L. Cancer associated fibroblasts: An essential role in the tumor
microenvironment. Oncol. Lett. 2017, 14, 2611–2620. [CrossRef]
20. Donnem, T.; Al-Saad, S.; Al-Shibli, K.; Andersen, S.; Busund, L.T.; Bremnes, R.M. Prognostic impact of
platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells. J. Thorac. Oncol. 2008,
3, 963–970. [CrossRef]
21. Edlund, K.; Lindskog, C.; Saito, A.; Berglund, A.; Ponten, F.; Goransson-Kultima, H.; Isaksson, A.; Jirstrom, K.;
Planck, M.; Johansson, L.; et al. CD99 is a novel prognostic stromal marker in non-small cell lung cancer.
Int. J. Cancer 2012, 131, 2264–2273. [CrossRef] [PubMed]
22. Saito, R.A.; Micke, P.; Paulsson, J.; Augsten, M.; Pena, C.; Jonsson, P.; Botling, J.; Edlund, K.; Johansson, L.;
Carlsson, P.; et al. Forkhead box F1 regulates tumor-promoting properties of cancer-associated fibroblasts in
lung cancer. Cancer Res. 2010, 70, 2644–2654. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 8635 12 of 15
23. Wu, C.Y.; Chan, C.H.; Dubey, N.K.; Wei, H.J.; Lu, J.H.; Chang, C.C.; Cheng, H.C.; Ou, K.L.; Deng, W.P.
Highly Expressed FOXF1 Inhibit Non-Small-Cell Lung Cancer Growth via Inducing Tumor Suppressor and
G1-Phase Cell-Cycle Arrest. Int. J. Mol. Sci. 2020, 21, 3227. [CrossRef] [PubMed]
24. Mattsson, J.S.; Bergman, B.; Grinberg, M.; Edlund, K.; Marincevic, M.; Jirstrom, K.; Ponten, F.; Hengstler, J.G.;
Rahnenfuhrer, J.; Karlsson, M.G.; et al. Prognostic impact of COX-2 in non-small cell lung cancer:
A comprehensive compartment-specific evaluation of tumor and stromal cell expression. Cancer Lett.
2015, 356, 837–845. [CrossRef] [PubMed]
25. Yokouchi, H.; Kanazawa, K. Revisiting the role of COX-2 inhibitor for non-small cell lung cancer. Transl. Lung
Cancer Res. 2015, 4, 660–664. [CrossRef]
26. Grinde, M.T.; Vik, J.; Camilio, K.A.; Martinez-Zubiaurre, I.; Hellevik, T. Ionizing radiation abrogates the
pro-tumorigenic capacity of cancer-associated fibroblasts co-implanted in xenografts. Sci. Rep. 2017, 7, 46714.
[CrossRef]
27. Martin, A.G.; Thomas, S.J.; Harden, S.V.; Burnet, N.G. Evaluating competing and emerging technologies for
stereotactic body radiotherapy and other advanced radiotherapy techniques. Clin. Oncol. 2015, 27, 251–259.
[CrossRef]
28. Eke, I.; Zong, D.; Aryankalayil, M.J.; Sandfort, V.; Bylicky, M.A.; Rath, B.H.; Graves, E.E.; Nussenzweig, A.;
Coleman, C.N. 53BP1/RIF1 signaling promotes cell survival after multifractionated radiotherapy.
Nucleic Acids Res. 2020, 48, 1314–1326. [CrossRef]
29. Mavragani, I.V.; Nikitaki, Z.; Kalospyros, S.A.; Georgakilas, A.G. Ionizing Radiation and Complex DNA
Damage: From Prediction to Detection Challenges and Biological Significance. Cancers 2019, 11, 1789.
[CrossRef]
30. Huang, R.X.; Zhou, P.K. DNA damage response signaling pathways and targets for radiotherapy sensitization
in cancer. Signal Transduct. Target. Ther. 2020, 5, 60. [CrossRef]
31. Piper, M.; Mueller, A.C.; Karam, S.D. The interplay between cancer associated fibroblasts and immune cells
in the context of radiation therapy. Mol. Carcinog. 2020, 59, 754–765. [CrossRef] [PubMed]
32. Matsuoka, Y.; Nakayama, H.; Yoshida, R.; Hirosue, A.; Nagata, M.; Tanaka, T.; Kawahara, K.; Sakata, J.;
Arita, H.; Nakashima, H.; et al. IL-6 controls resistance to radiation by suppressing oxidative stress via the
Nrf2-antioxidant pathway in oral squamous cell carcinoma. Br. J. Cancer 2016, 115, 1234–1244. [CrossRef]
[PubMed]
33. Chen, Y.; Zhang, F.; Tsai, Y.; Yang, X.; Yang, L.; Duan, S.; Wang, X.; Keng, P.; Lee, S.O. IL-6 signaling promotes
DNA repair and prevents apoptosis in CD133+ stem-like cells of lung cancer after radiation. Radiat. Oncol.
2015, 10, 227. [CrossRef] [PubMed]
34. Castaneda-Zegarra, S.; Fernandez-Berrocal, M.; Tkachev, M.; Yao, R.; Upfold, N.L.E.; Oksenych, V. Genetic
interaction between the non-homologous end joining factors during B and T lymphocyte development:
In vivo mouse models. Scand. J. Immunol. 2020, e12936. [CrossRef]
35. Kumar, V.; Alt, F.W.; Oksenych, V. Functional overlaps between XLF and the ATM-dependent DNA double
strand break response. DNA Repair 2014, 16, 11–22. [CrossRef] [PubMed]
36. Wang, X.S.; Lee, B.J.; Zha, S. The recent advances in non-homologous end-joining through the lens of
lymphocyte development. DNA Repair 2020, 94, 102874. [CrossRef]
37. Ponath, V.; Heylmann, D.; Haak, T.; Woods, K.; Becker, H.; Kaina, B. Compromised DNA Repair and
Signalling in Human Granulocytes. J. Innate Immun. 2019, 11, 74–85. [CrossRef]
38. Briegert, M.; Kaina, B. Human monocytes, but not dendritic cells derived from them, are defective in base
excision repair and hypersensitive to methylating agents. Cancer Res. 2007, 67, 26–31. [CrossRef]
39. Bauer, M.; Goldstein, M.; Christmann, M.; Becker, H.; Heylmann, D.; Kaina, B. Human monocytes are
severely impaired in base and DNA double-strand break repair that renders them vulnerable to oxidative
stress. Proc. Natl. Acad. Sci. USA 2011, 108, 21105–21110. [CrossRef]
40. Bauer, M.; Goldstein, M.; Heylmann, D.; Kaina, B. Human monocytes undergo excessive apoptosis following
temozolomide activating the ATM/ATR pathway while dendritic cells and macrophages are resistant.
PLoS ONE 2012, 7, e39956. [CrossRef]
41. Ponath, V.; Kaina, B. Death of Monocytes through Oxidative Burst of Macrophages and Neutrophils: Killing
in Trans. PLoS ONE 2017, 12, e0170347. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 8635 13 of 15
42. Hald, S.M.; Rakaee, M.; Martinez, I.; Richardsen, E.; Al-Saad, S.; Paulsen, E.E.; Blix, E.S.; Kilvaer, T.;
Andersen, S.; Busund, L.T.; et al. LAG-3 in Non-Small-cell Lung Cancer: Expression in Primary Tumors and
Metastatic Lymph Nodes Is Associated With Improved Survival. Clin. Lung Cancer 2018, 19, 249–259.e242.
[CrossRef] [PubMed]
43. Wang, J.H. Why the Outcome of Anti-Tumor Immune Responses is Heterogeneous: A Novel Idea in the
Context of Immunological Heterogeneity in Cancers. Bioessays 2020, e2000024. [CrossRef] [PubMed]
44. Manda, K.; Glasow, A.; Paape, D.; Hildebrandt, G. Effects of ionizing radiation on the immune system with
special emphasis on the interaction of dendritic and T cells. Front. Oncol. 2012, 2, 102. [CrossRef] [PubMed]
45. Liu, S.; Sun, X.; Luo, J.; Zhu, H.; Yang, X.; Guo, Q.; Song, Y.; Sun, X. Effects of radiation on T regulatory cells
in normal states and cancer: Mechanisms and clinical implications. Am. J. Cancer Res. 2015, 5, 3276–3285.
[PubMed]
46. Anton, D.; Dabadghao, S.; Palucka, K.; Holm, G.; Yi, Q. Generation of dendritic cells from peripheral blood
adherent cells in medium with human serum. Scand. J. Immunol. 1998, 47, 116–121. [CrossRef] [PubMed]
47. Cao, M.D.; Chen, Z.D.; Xing, Y. Gamma irradiation of human dendritic cells influences proliferation and
cytokine profile of T cells in autologous mixed lymphocyte reaction. Cell Biol. Int. 2004, 28, 223–228.
[CrossRef] [PubMed]
48. Nishii, K.; Gibbons, D.L.; Titley, I.; Papworth, D.; Goodhead, D.T.; Greaves, M. Regulation of the apoptotic
response to radiation damage in B cell development. Cell Death Differ. 1998, 5, 77–86. [CrossRef]
49. Deriano, L.; Guipaud, O.; Merle-Beéral, H.L.N.; Binet, J.-L.; Ricoul, M.; Potocki-Veronese, G.; Favaudon, V.;
Maciorowski, Z.; Muller, C.; Salles, B.; et al. Human chronic lymphocytic leukemia B cells can escape DNA
damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway. Blood 2005,
105, 4776–4783. [CrossRef]
50. Chen, J.; Liu, X.; Zeng, Z.; Li, J.; Luo, Y.; Sun, W.; Gong, Y.; Zhang, J.; Wu, Q.; Xie, C. Immunomodulation of
NK Cells by Ionizing Radiation. Front. Oncol. 2020, 10, 874. [CrossRef]
51. Zarcone, D.; Tilden, A.B.; Lane, V.G.; Grossi, C.E. Radiation sensitivity of resting and activated nonspecific
cytotoxic cells of T lineage and NK lineage. Blood 1989, 73, 1615–1621. [CrossRef] [PubMed]
52. Hietanen, T.; Pitkanen, M.; Kapanen, M.; Kellokumpu-Lehtinen, P.L. Effects of Single and Fractionated
Irradiation on Natural Killer Cell Populations: Radiobiological Characteristics of Viability and Cytotoxicity
In Vitro. Anticancer Res. 2015, 35, 5193–5200. [PubMed]
53. Kim, S.S.; Shen, S.; Miyauchi, S.; Sanders, P.D.; Franiak-Pietryga, I.; Mell, L.; Gutkind, J.S.; Cohen, E.E.W.;
Califano, J.A.; Sharabi, A.B. B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas
and Are Activated by Radiation and PD-1 Blockade. Clin. Cancer Res. 2020, 26, 3345. [CrossRef]
54. Kunala, S.; Macklis, R.M. Ionizing radiation induces CD20 surface expression on human B cells. Int. J. Cancer
2001, 96, 178–181. [CrossRef] [PubMed]
55. Heylmann, D.; Rödel, F.; Kindler, T.; Kaina, B. Radiation sensitivity of human and murine peripheral blood
lymphocytes, stem and progenitor cells. Biochim. Biophys. Acta Rev. Cancer 2014, 1846, 121–129. [CrossRef]
[PubMed]
56. Bjorkman, A.; Du, L.; Felgentreff, K.; Rosner, C.; Kamdar, R.P.; Kokaraki, G.; Matsumoto, Y.; Davies, E.G.;
van der Burg, M.; Notarangelo, L.D.; et al. DNA-PKcs Is Involved in Ig Class Switch Recombination in
Human B Cells. J. Immunol. 2015, 195, 5608–5615. [CrossRef] [PubMed]
57. Oksenych, V.; Kumar, V.; Liu, X.; Guo, C.; Schwer, B.; Zha, S.; Alt, F.W. Functional redundancy between the
XLF and DNA-PKcs DNA repair factors in V(D)J recombination and nonhomologous DNA end joining.
Proc. Natl. Acad. Sci. USA 2013, 110, 2234–2239. [CrossRef]
58. Boboila, C.; Oksenych, V.; Gostissa, M.; Wang, J.H.; Zha, S.; Zhang, Y.; Chai, H.; Lee, C.S.; Jankovic, M.;
Saez, L.M.; et al. Robust chromosomal DNA repair via alternative end-joining in the absence of X-ray repair
cross-complementing protein 1 (XRCC1). Proc. Natl. Acad. Sci. USA 2012, 109, 2473–2478. [CrossRef]
59. Goans, R.E.; Waselenko, J.K. Medical management of radiological casualties. Health Phys. 2005, 89, 505–512.
[CrossRef]
60. Alvarez, M.; Simonetta, F.; Baker, J.; Pierini, A.; Wenokur, A.S.; Morrison, A.R.; Murphy, W.J.; Negrin, R.S.
Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway.
JCI Insight 2019, 5. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 8635 14 of 15
61. Kraman, M.; Bambrough, P.J.; Arnold, J.N.; Roberts, E.W.; Magiera, L.; Jones, J.O.; Gopinathan, A.;
Tuveson, D.A.; Fearon, D.T. Suppression of antitumor immunity by stromal cells expressing fibroblast
activation protein-alpha. Science 2010, 330, 827–830. [CrossRef] [PubMed]
62. Orimo, A.; Weinberg, R.A. Stromal fibroblasts in cancer: A novel tumor-promoting cell type. Cell Cycle 2006,
5, 1597–1601. [CrossRef] [PubMed]
63. Ito, M.; Ishii, G.; Nagai, K.; Maeda, R.; Nakano, Y.; Ochiai, A. Prognostic impact of cancer-associated stromal
cells in patients with stage I lung adenocarcinoma. Chest 2012, 142, 151–158. [CrossRef] [PubMed]
64. Xuan, W.; Qu, Q.; Zheng, B.; Xiong, S.; Fan, G.H. The chemotaxis of M1 and M2 macrophages is regulated by
different chemokines. J. Leukoc. Biol. 2015, 97, 61–69. [CrossRef] [PubMed]
65. Wculek, S.K.; Cueto, F.J.; Mujal, A.M.; Melero, I.; Krummel, M.F.; Sancho, D. Dendritic cells in cancer
immunology and immunotherapy. Nat. Rev. Immunol. 2020, 20, 7–24. [CrossRef] [PubMed]
66. Hsu, Y.L.; Hung, J.Y.; Chiang, S.Y.; Jian, S.F.; Wu, C.Y.; Lin, Y.S.; Tsai, Y.M.; Chou, S.H.; Tsai, M.J.; Kuo, P.L.
Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and
immune suppression through TDO2/kynurenine axis. Oncotarget 2016, 7, 27584–27598. [CrossRef]
67. Cheng, J.T.; Deng, Y.N.; Yi, H.M.; Wang, G.Y.; Fu, B.S.; Chen, W.J.; Liu, W.; Tai, Y.; Peng, Y.W.; Zhang, Q. Hepatic
carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated
STAT3 activation. Oncogenesis 2016, 5, e198. [CrossRef]
68. De Monte, L.; Reni, M.; Tassi, E.; Clavenna, D.; Papa, I.; Recalde, H.; Braga, M.; Di Carlo, V.; Doglioni, C.;
Protti, M.P. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic
stromal lymphopoietin production and reduced survival in pancreatic cancer. J. Exp. Med. 2011, 208, 469–478.
[CrossRef]
69. Vivier, E.; Raulet, D.H.; Moretta, A.; Caligiuri, M.A.; Zitvogel, L.; Lanier, L.L.; Yokoyama, W.M.; Ugolini, S.
Innate or adaptive immunity? The example of natural killer cells. Science 2011, 331, 44–49. [CrossRef]
70. Rydyznski, C.E.; Waggoner, S.N. Boosting vaccine efficacy the natural (killer) way. Trends Immunol. 2015,
36, 536–546. [CrossRef]
71. Hall, E.J.; Giaccia, A.J. Radiobiology for the Radiologist; Lippincott Williams & Wilkins: Philadelphia, PA, USA,
2006; Volume 6.
72. Kugeratski, F.G.; Atkinson, S.J.; Neilson, L.J.; Lilla, S.; Knight, J.R.P.; Serneels, J.; Juin, A.; Ismail, S.;
Bryant, D.M.; Markert, E.K.; et al. Hypoxic cancer-associated fibroblasts increase NCBP2-AS2/HIAR to
promote endothelial sprouting through enhanced VEGF signaling. Sci. Signal. 2019, 12. [CrossRef] [PubMed]
73. Petrova, V.; Annicchiarico-Petruzzelli, M.; Melino, G.; Amelio, I. The hypoxic tumour microenvironment.
Oncogenesis 2018, 7, 10. [CrossRef] [PubMed]
74. Laitala, A.; Erler, J.T. Hypoxic Signalling in Tumour Stroma. Front. Oncol. 2018, 8, 189. [CrossRef] [PubMed]
75. Tang, Y.A.; Chen, Y.F.; Bao, Y.; Mahara, S.; Yatim, S.; Oguz, G.; Lee, P.L.; Feng, M.; Cai, Y.; Tan, E.Y.; et al.
Hypoxic tumor microenvironment activates GLI2 via HIF-1alpha and TGF-beta2 to promote chemoresistance
in colorectal cancer. Proc. Natl. Acad. Sci. USA 2018, 115, E5990–E5999. [CrossRef] [PubMed]
76. Lappano, R.; Talia, M.; Cirillo, F.; Rigiracciolo, D.C.; Scordamaglia, D.; Guzzi, R.; Miglietta, A.M.;
De Francesco, E.M.; Belfiore, A.; Sims, A.H.; et al. The IL1beta-IL1R signaling is involved in the stimulatory
effects triggered by hypoxia in breast cancer cells and cancer-associated fibroblasts (CAFs). J. Exp. Clin.
Cancer Res. 2020, 39, 153. [CrossRef]
77. Ianevski, A.; Kulesskiy, E.; Krpina, K.; Lou, G.; Aman, Y.; Bugai, A.; Aasumets, K.; Akimov, Y.; Bulanova, D.;
Gildemann, K.; et al. Chemical, Physical and Biological Triggers of Evolutionary Conserved Bcl-xL-Mediated
Apoptosis. Cancers 2020, 12, 1694. [CrossRef]
78. Bulanova, D.; Ianevski, A.; Bugai, A.; Akimov, Y.; Kuivanen, S.; Paavilainen, H.; Kakkola, L.; Nandania, J.;
Turunen, L.; Ohman, T.; et al. Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2
Proteins. Viruses 2017, 9, 271. [CrossRef]
79. Kakkola, L.; Denisova, O.V.; Tynell, J.; Viiliainen, J.; Ysenbaert, T.; Matos, R.C.; Nagaraj, A.; Ohman, T.;
Kuivanen, S.; Paavilainen, H.; et al. Anticancer compound ABT-263 accelerates apoptosis in virus-infected
cells and imbalances cytokine production and lowers survival rates of infected mice. Cell Death Dis. 2013,
4, e742. [CrossRef]
80. Denisova, O.V.; Kakkola, L.; Feng, L.; Stenman, J.; Nagaraj, A.; Lampe, J.; Yadav, B.; Aittokallio, T.;
Kaukinen, P.; Ahola, T.; et al. Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus
infection. J. Biol. Chem. 2012, 287, 35324–35332. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 8635 15 of 15
81. Shim, J.M.; Kim, J.; Tenson, T.; Min, J.Y.; Kainov, D.E. Influenza Virus Infection, Interferon Response, Viral
Counter-Response, and Apoptosis. Viruses 2017, 9, 223. [CrossRef]
82. Ianevski, A.; Yao, R.; Biza, S.; Zusinaite, E.; Mannik, A.; Kivi, G.; Planken, A.; Kurg, K.; Tombak, E.M.;
Ustav, M., Jr.; et al. Identification and Tracking of Antiviral Drug Combinations. Viruses 2020, 12, 1178.
[CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional
affiliations.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
